17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analogues

J R Falck; Gerd Wallukat; Narender Puli; Mohan Goli; Cosima Arnold; Anne Konkel; Michael Rothe; Robert Fischer; Dominik N. Müller; Wolf Hagen Schunck

doi:10.1021/jm200132q

17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analogues

J R Falck, Gerd Wallukat, Narender Puli, Mohan Goli, Cosima Arnold, Anne Konkel, Michael Rothe, Robert Fischer, Dominik N. Müller, Wolf Hagen Schunck

Biochemistry

Research output: Contribution to journal › Article › peer-review

59 Scopus citations

Abstract

17(R),18(S)-Epoxyeicosatetraenoic acid [17(R),18(S)-EETeTr], a cytochrome P450 epoxygenase metabolite of eicosapentaenoic acid (EPA), exerts negative chronotropic effects and protects neonatal rat cardiomyocytes against Ca ²⁺-overload with EC₅₀ ≈ 1-2 nM. Structure-activity studies revealed that a cis-Δ^11,12- or Δ^14,15- olefin and a 17(R),18(S)-epoxide are minimal structural elements for antiarrhythmic activity whereas antagonist activity was often associated with the combination of a Δ^14,15-olefin and a 17(S),18(R)-epoxide. Compared with natural material, the agonist and antagonist analogues are chemically and metabolically more robust and several show promise as templates for future development of clinical candidates.

Original language	English (US)
Pages (from-to)	4109-4118
Number of pages	10
Journal	Journal of Medicinal Chemistry
Volume	54
Issue number	12
DOIs	https://doi.org/10.1021/jm200132q
State	Published - Jun 23 2011

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1021/jm200132q

Cite this

Falck, J. R., Wallukat, G., Puli, N., Goli, M., Arnold, C., Konkel, A., Rothe, M., Fischer, R., Müller, D. N., & Schunck, W. H. (2011). 17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analogues. Journal of Medicinal Chemistry, 54(12), 4109-4118. https://doi.org/10.1021/jm200132q

17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analogues. / Falck, J R; Wallukat, Gerd; Puli, Narender et al.
In: Journal of Medicinal Chemistry, Vol. 54, No. 12, 23.06.2011, p. 4109-4118.

Research output: Contribution to journal › Article › peer-review

Falck, JR, Wallukat, G, Puli, N, Goli, M, Arnold, C, Konkel, A, Rothe, M, Fischer, R, Müller, DN & Schunck, WH 2011, '17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analogues', Journal of Medicinal Chemistry, vol. 54, no. 12, pp. 4109-4118. https://doi.org/10.1021/jm200132q

@article{6e05dfce3c614c2c904295f6d44aa2da,

title = "17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analogues",

abstract = "17(R),18(S)-Epoxyeicosatetraenoic acid [17(R),18(S)-EETeTr], a cytochrome P450 epoxygenase metabolite of eicosapentaenoic acid (EPA), exerts negative chronotropic effects and protects neonatal rat cardiomyocytes against Ca 2+-overload with EC50 ≈ 1-2 nM. Structure-activity studies revealed that a cis-Δ11,12- or Δ14,15- olefin and a 17(R),18(S)-epoxide are minimal structural elements for antiarrhythmic activity whereas antagonist activity was often associated with the combination of a Δ14,15-olefin and a 17(S),18(R)-epoxide. Compared with natural material, the agonist and antagonist analogues are chemically and metabolically more robust and several show promise as templates for future development of clinical candidates.",

author = "Falck, {J R} and Gerd Wallukat and Narender Puli and Mohan Goli and Cosima Arnold and Anne Konkel and Michael Rothe and Robert Fischer and M{\"u}ller, {Dominik N.} and Schunck, {Wolf Hagen}",

year = "2011",

month = jun,

day = "23",

doi = "10.1021/jm200132q",

language = "English (US)",

volume = "54",

pages = "4109--4118",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "12",

}

TY - JOUR

T1 - 17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction

T2 - Structure-activity relationships and stable analogues

AU - Falck, J R

AU - Wallukat, Gerd

AU - Puli, Narender

AU - Goli, Mohan

AU - Arnold, Cosima

AU - Konkel, Anne

AU - Rothe, Michael

AU - Fischer, Robert

AU - Müller, Dominik N.

AU - Schunck, Wolf Hagen

PY - 2011/6/23

Y1 - 2011/6/23

N2 - 17(R),18(S)-Epoxyeicosatetraenoic acid [17(R),18(S)-EETeTr], a cytochrome P450 epoxygenase metabolite of eicosapentaenoic acid (EPA), exerts negative chronotropic effects and protects neonatal rat cardiomyocytes against Ca 2+-overload with EC50 ≈ 1-2 nM. Structure-activity studies revealed that a cis-Δ11,12- or Δ14,15- olefin and a 17(R),18(S)-epoxide are minimal structural elements for antiarrhythmic activity whereas antagonist activity was often associated with the combination of a Δ14,15-olefin and a 17(S),18(R)-epoxide. Compared with natural material, the agonist and antagonist analogues are chemically and metabolically more robust and several show promise as templates for future development of clinical candidates.

AB - 17(R),18(S)-Epoxyeicosatetraenoic acid [17(R),18(S)-EETeTr], a cytochrome P450 epoxygenase metabolite of eicosapentaenoic acid (EPA), exerts negative chronotropic effects and protects neonatal rat cardiomyocytes against Ca 2+-overload with EC50 ≈ 1-2 nM. Structure-activity studies revealed that a cis-Δ11,12- or Δ14,15- olefin and a 17(R),18(S)-epoxide are minimal structural elements for antiarrhythmic activity whereas antagonist activity was often associated with the combination of a Δ14,15-olefin and a 17(S),18(R)-epoxide. Compared with natural material, the agonist and antagonist analogues are chemically and metabolically more robust and several show promise as templates for future development of clinical candidates.

UR - http://www.scopus.com/inward/record.url?scp=79959434105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959434105&partnerID=8YFLogxK

U2 - 10.1021/jm200132q

DO - 10.1021/jm200132q

M3 - Article

C2 - 21591683

AN - SCOPUS:79959434105

SN - 0022-2623

VL - 54

SP - 4109

EP - 4118

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 12

ER -

17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analogues

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this